Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension.

Humans Middle Aged Hypertension, Pulmonary / metabolism Lung / metabolism Lung Diseases, Interstitial / metabolism Prognosis Scleroderma, Systemic / metabolism Oxyhemoglobins / metabolism

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
01 02 2023
Historique:
received: 28 09 2022
accepted: 20 01 2023
entrez: 1 2 2023
pubmed: 2 2 2023
medline: 4 2 2023
Statut: epublish

Résumé

Oxygenated hemoglobin (OxyHem) in arterial blood may reflect disease severity in patients with systemic sclerosis (SSc). The aim of this study was to analyze the predictive value of OxyHem in SSc patients screened for pulmonary hypertension (PH). OxyHem (g/dl) was measured by multiplying the concentration of hemoglobin with fractional oxygen saturation in arterialized capillary blood. Prognostic power was compared with known prognostic parameters in SSc using uni- and multivariable analysis. A total of 280 SSc patients were screened, 267 were included in the analysis. No signs of pulmonary vascular disease were found in 126 patients, while 141 patients presented with mean pulmonary arterial pressure ≥ 21 mmHg. Interstitial lung disease (ILD) was identified in 70 patients. Low OxyHem ≤ 12.5 g/dl at baseline was significantly associated with worse survival (P = 0.046). In the multivariable analysis presence of ILD, age ≥ 60 years and diffusion capacity for carbon monoxide (DLCO) ≤ 65% were negatively associated with survival. The combination of low DLCO and low OxyHem at baseline could predict PH at baseline (sensitivity 76.1%). This study detected for the first time OxyHem ≤ 12.5 g/dl as a prognostic predictor in SSc patients. Further studies are needed to confirm these results.

Identifiants

DOI: 10.1038/s41598-023-28608-x PMID: 36725894 PMC: PMC9892512
pubmed: 36725894
doi: 10.1038/s41598-023-28608-x
pii: 10.1038/s41598-023-28608-x
pmc: PMC9892512
doi:

Substances chimiques

Oxyhemoglobins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1839

Informations de copyright

© 2023. The Author(s).

Références

Elhai, M. et al. Mapping and predicting mortality from systemic sclerosis. Ann. Rheum Dis. 76, 1897–1905. https://doi.org/10.1136/annrheumdis-2017-211448 (2017).
doi: 10.1136/annrheumdis-2017-211448
Elhai, M., Meune, C., Avouac, J., Kahan, A. & Allanore, Y. Trends in mortality in patients with systemic sclerosis over 40 years: A systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 51, 1017–1026. https://doi.org/10.1093/rheumatology/ker269 (2012).
doi: 10.1093/rheumatology/ker269
Toledano, E. et al. A meta-analysis of mortality in rheumatic diseases. Reumatol. Clin. 8, 334–341. https://doi.org/10.1016/j.reuma.2012.05.006 (2012).
doi: 10.1016/j.reuma.2012.05.006
Wu, W. et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: The SPAR model. Ann. Rheum Dis. 77, 1326–1332. https://doi.org/10.1136/annrheumdis-2018-213201 (2018).
doi: 10.1136/annrheumdis-2018-213201
Swigris, J. J. et al. Exercise peripheral oxygen saturation (SpO
doi: 10.1136/thx.2008.111393
Ruiter, G. et al. Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology 53, 285–292. https://doi.org/10.1093/rheumatology/ket331 (2014).
doi: 10.1093/rheumatology/ket331
Trudzinski, F. C. et al. Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET. Sci. Rep. 10, 10544. https://doi.org/10.1038/s41598-020-67197-x (2020).
doi: 10.1038/s41598-020-67197-x
Hinke, C. F. et al. Prognostic value of oxygenated hemoglobin assessed during acute exacerbations of chronic pulmonary disease. Respiration 100, 387–394. https://doi.org/10.1159/000513440 (2021).
doi: 10.1159/000513440
Galiè, N. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 37, 67–119. https://doi.org/10.1093/eurheartj/ehv317 (2016).
doi: 10.1093/eurheartj/ehv317
Coghlan, J. G. et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: The DETECT study. Ann. Rheum Dis. 73, 1340–1349. https://doi.org/10.1136/annrheumdis-2013-203301 (2014).
doi: 10.1136/annrheumdis-2013-203301
van Hal, T. W., van Bon, L. & Radstake, T. R. A system out of breath: How hypoxia possibly contributes to the pathogenesis of systemic sclerosis. Int J Rheumatol 2011, 824972. https://doi.org/10.1155/2011/824972 (2011).
doi: 10.1155/2011/824972
Pokeerbux, M. R. et al. Survival and prognosis factors in systemic sclerosis: Data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res. Ther. 21, 86. https://doi.org/10.1186/s13075-019-1867-1 (2019).
doi: 10.1186/s13075-019-1867-1
Nihtyanova, S. I. et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 66, 1625–1635. https://doi.org/10.1002/art.38390 (2014).
doi: 10.1002/art.38390
Fransen, J. et al. Clinical prediction of 5-year survival in systemic sclerosis: Validation of a simple prognostic model in EUSTAR centres. Ann. Rheum Dis. 70, 1788–1792. https://doi.org/10.1136/ard.2010.144360 (2011).
doi: 10.1136/ard.2010.144360
Panopoulos, S. et al. Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort. Autoimmun. Rev. 17, 816–820. https://doi.org/10.1016/j.autrev.2018.02.008 (2018).
doi: 10.1016/j.autrev.2018.02.008
Valentini, G. et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index. Ann. Rheum Dis. 76, 270–276. https://doi.org/10.1136/annrheumdis-2016-209768 (2017).
doi: 10.1136/annrheumdis-2016-209768
Hsu, V. M. et al. Risk factors for mortality and cardiopulmonary hospitalization in systemic sclerosis patients at risk for pulmonary hypertension, in the PHAROS registry. J. Rheumatol. 46, 176–183. https://doi.org/10.3899/jrheum.180018 (2019).
doi: 10.3899/jrheum.180018
Gadre, A. et al. Six-minute walk test as a predictor of diagnosis, disease severity, and clinical outcomes in Scleroderma-associated pulmonary hypertension: The DIBOSA study. Lung 195, 529–536. https://doi.org/10.1007/s00408-017-0034-1 (2017).
doi: 10.1007/s00408-017-0034-1
Hoeper, M. M., Pletz, M. W., Golpon, H. & Welte, T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 29, 944–950. https://doi.org/10.1183/09031936.00134506 (2007).
doi: 10.1183/09031936.00134506
Valentin, S. et al. Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. Eur. Respir. J. https://doi.org/10.1183/13993003.04066-2020 (2021).
doi: 10.1183/13993003.04066-2020
Al-Dhaher, F. F., Pope, J. E. & Ouimet, J. M. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin. Arthritis Rheum 39, 269–277. https://doi.org/10.1016/j.semarthrit.2008.06.002 (2010).
doi: 10.1016/j.semarthrit.2008.06.002
Volkmann, E. R. et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann. Rheum Dis. 78, 122–130. https://doi.org/10.1136/annrheumdis-2018-213708 (2019).
doi: 10.1136/annrheumdis-2018-213708
Langlands, J. H. & Wallace, W. F. Small blood-samples from ear-lobe puncture: A substitute for arterial puncture. Lancet 2, 315–317. https://doi.org/10.1016/s0140-6736(65)90286-2 (1965).
doi: 10.1016/s0140-6736(65)90286-2
LeRoy, E. C. & Medsger, T. A. Jr. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28, 1573–1576 (2001).
van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65, 2737–2747. https://doi.org/10.1002/art.38098 (2013).
doi: 10.1002/art.38098
Xanthouli, P. et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: The impact of the new definition of pulmonary arterial hypertension. Ann. Rheum Dis. 79, 370–378. https://doi.org/10.1136/annrheumdis-2019-216476 (2020).
doi: 10.1136/annrheumdis-2019-216476
Guyatt, G. H. et al. Effect of encouragement on walking test performance. Thorax 39, 818–822 (1984).
doi: 10.1136/thx.39.11.818
Goh, N. S. et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am. J. Respir. Crit. Care Med. 177, 1248–1254. https://doi.org/10.1164/rccm.200706-877OC (2008).
doi: 10.1164/rccm.200706-877OC
Humbert, M. et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehac237 (2022).
doi: 10.1093/eurheartj/ehac237
Nathan, S. D. et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur. Respir. J. https://doi.org/10.1183/13993003.01914-2018 (2018).
doi: 10.1183/13993003.01914-2018
Chung, L. et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: Outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res. (Hoboken) 66, 489–495. https://doi.org/10.1002/acr.22121 (2014).
doi: 10.1002/acr.22121

Auteurs

Panagiota Xanthouli (P)

Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Röntgenstrasse 1, 69126, Heidelberg, Germany.
Translational Lung Research Center Heidelberg (TLRC), the German Center for Lung Research (DZL), Heidelberg, Germany.
Department of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Heidelberg, Germany.
Division of Rheumatology, Department of Internal Medicine V: Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.

Ojan Gordjani (O)

Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Röntgenstrasse 1, 69126, Heidelberg, Germany.

Nicola Benjamin (N)

Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Röntgenstrasse 1, 69126, Heidelberg, Germany.
Translational Lung Research Center Heidelberg (TLRC), the German Center for Lung Research (DZL), Heidelberg, Germany.

Franziska C Trudzinski (FC)

Translational Lung Research Center Heidelberg (TLRC), the German Center for Lung Research (DZL), Heidelberg, Germany.
Department of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Heidelberg, Germany.

Benjamin Egenlauf (B)

Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Röntgenstrasse 1, 69126, Heidelberg, Germany.
Translational Lung Research Center Heidelberg (TLRC), the German Center for Lung Research (DZL), Heidelberg, Germany.
Department of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Heidelberg, Germany.

Satenik Harutyunova (S)

Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Röntgenstrasse 1, 69126, Heidelberg, Germany.
Translational Lung Research Center Heidelberg (TLRC), the German Center for Lung Research (DZL), Heidelberg, Germany.
Department of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Heidelberg, Germany.

Alberto M Marra (AM)

Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Röntgenstrasse 1, 69126, Heidelberg, Germany.
Translational Lung Research Center Heidelberg (TLRC), the German Center for Lung Research (DZL), Heidelberg, Germany.
Department of Translational Medical Sciences, "Federico II" University and School of Medicine, Naples, Italy.

Nicklas Milde (N)

Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Röntgenstrasse 1, 69126, Heidelberg, Germany.

Christian Nagel (C)

Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Röntgenstrasse 1, 69126, Heidelberg, Germany.
Department of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Heidelberg, Germany.
Department of Respiratory Care Medicine and Thoracic Surgery, Klinikum Mittelbaden, Baden-Baden Balg, Baden-Baden, Germany.

Norbert Blank (N)

Division of Rheumatology, Department of Internal Medicine V: Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.

Hanns-Martin Lorenz (HM)

Division of Rheumatology, Department of Internal Medicine V: Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.

Ekkehard Grünig (E)

Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Röntgenstrasse 1, 69126, Heidelberg, Germany.
Translational Lung Research Center Heidelberg (TLRC), the German Center for Lung Research (DZL), Heidelberg, Germany.
Department of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Heidelberg, Germany.

Christina A Eichstaedt (CA)

Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Röntgenstrasse 1, 69126, Heidelberg, Germany. christina.eichstaedt@med.uni-heidelberg.de.
Translational Lung Research Center Heidelberg (TLRC), the German Center for Lung Research (DZL), Heidelberg, Germany. christina.eichstaedt@med.uni-heidelberg.de.
Laboratory for Molecular Genetic Diagnostics, Institute of Human Genetics, Heidelberg University, Heidelberg, Germany. christina.eichstaedt@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Oxygenated hemoglobin as prognostic marker...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Oxygenated hemoglobin as prognostic marker...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Hypertension artérielle › Hypertension pulmonaire › Oxygenated hemoglobin as prognostic marker...
questionsmedicales.fr › Appareil respiratoire › Poumon › Oxygenated hemoglobin as prognostic marker...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Maladies pulmonaires › Pneumopathies interstitielles › Oxygenated hemoglobin as prognostic marker...
questionsmedicales.fr › Diagnostic › Pronostic › Oxygenated hemoglobin as prognostic marker...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Sclérodermie systémique › Oxygenated hemoglobin as prognostic marker...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Hémoprotéines › Globines › Hémoglobines › Oxyhémoglobines › Oxygenated hemoglobin as prognostic marker...